SlideShare a Scribd company logo
1 of 28
CASE PRESENTATION
DEMOGRAPHIC DETAILS
Patient Name :XYZ
Age : 53 years
Gender : Male
Weight : 89 kg
Height : 172 cm
BMI : 30kg/m2 (Obese)
DOA : 21.12.2020
DOD : 24.12.2020
PROBLEM LIST
Hypertension
Type 2 Diabetes Mellitus
Hyperlipidemia
SUBJECTIVE EVIDENCE
COMPLAINTS ON ADMISSION:
 Generalised weakness since 1 month.
 Instability while walking.
 Excessive sweating.
 Rapid breathing.
 Chronic headache since 1 week.
OBJECTIVE EVIDENCE
PHYSICAL EXAMINATION :
Conscious , Co-Operative
P-I-C-CL-E (-)
MEDICAL HISTORY:
Type 2 Diabetes mellitus since 1 years.
Hypertension since 2 year.
MEDICATION HISTORY:
GLIMEPIRIDE 2mg 1-0-1
ATENOLOL 50mg 0-1-0
 SOCIAL HISTORY:
Alcoholic
 FAMILY HISTORY:
Nil
GENERAL EXAMINATION
VITAL SIGNS:
Blood pressure -160/100 mmHg.
Respiratory rate - 27 cycles/min.
Heart rate - 84 bpm.
Temperature - 99° F.
LABORATORY INVESTIGATIONS
BLOOD GLUCOSE:
RBS (110-180 mg/dl) : 310mg/dl
FBS ( 70- 100 mg/dl) : 160 mg/dl
HbA1c (4-6) : 7.8
LIPID PROFILE:
TCh ( 120-200 mg/dl) : 280mg/dl
TGs ( upto 170 mg/dl) : 240mg/dl
HDL ( 40-60 mg/dl) : 34 mg/dl
LDL ( 100-160 mg/dl) : 204 mg/dl
HAEMATOLOGY:
RBC (4.5-5.5 million cells/cmm) : 5.3
WBC (4,000-11,000 cells/cmm) :7000
Platelet(1.5L-3.0L) :2.5L
Hb ( 13.5- 17.5 g/dl ) : 14.6 g/dl
ESR ( 0-20 mm/h) : 20 mm/h
LIVER:
T.Bili (0.2-1.2 mg/dl) :0.24 mg/dl
D.Bili (0-0.3 mg/dl) :0.08 mg/dl
ALP (110-310 IU/L) :290 IU/L
Albumin (3.2-5.5 g/dl) :4.8 g/dl
Globulin(1.8-3.4 g/dl) : 3.0g/dl
RENAL FUNCTION TESTS:
Urea (10-45 mg/dl) : 38mg/dl
Serum creatinine (0.4-1.4 mg/dl) :1.0 mg/dl
ELECTROLYTES:
Na (135-145 mEq/L) :140 mEq/L
K (3.5-5 mEq/L) :3.8mEq/L
Ca (8.8-10.2 mg/L) :9.2 mg/dl
DAILY INVESTIGATION CHART:
DAY INVESTIGATIONS
DAY 2 FBS - 150mg/dl
BP - 160/95 mmHg
TC - 230 mg/dl
LDL - 185 mg/dl
HDL - 38 mg/dl
DAY 3 FBS - 140 mg/dl
BP - 140/90 mmHg
TC - 218 mg/dl
LDL - 170 mg/dl
HDL - 48 mg/dl
DAY 4 FBS - 140mg/dl
BP - 140/85 mg/dl
TC - 204 mg/dl
LDL - 164 mg/dl
HDL - 54 mg/dl
DAY INSULIN AFTER
BREAKFA
ST
INSULI
N
AFTER
LUNCH
INSULI
N
AFTER
DINNE
R
1
8U 310 8U 280 8U 300
2 8U 260 8U 240 8U 240
ASSESSMENT
DIAGNOSIS:
Based on the subjective and objective evidence the patient
was diagnosed with Type 2 Diabetes mellitus, Hypertension along
with Hyperlipidemia.
ETIOLOGY:
Age
Alcoholic
CURRENT THERAPY
The Following Medications have been Prescribed to the Patient-
GENERIC NAME BRAND NAME DOSE ROA FREQUENCY DURATION
DAY1 DAY2 DAY3 DAY4
INSULIN INJ.
H.ACTRAPID
(40IU/ml)
8U SC 1-1-1  
T.METFORMIN APO.METFORM
IN
500 mg P/O 0-0-1    
T.TELMISARTAN T.TELMA 40 mg P/O 0-1-0    
ASPIRIN+ATORV
ASTATIN
CAP.ECOSPRIN
AV 75
75 mg/ P/O
10 mg
0-0-1    
MULTIVITAMIN T.OPTINEURON 15 mg P/O 1-0-1    
PARACETAMOL T.DOLO 650mg P/O 1-0-0   SOS
INJ. H.ACTRAPID(40IU/ml) SC
 Category: Anti – diabetic
 Indication: Diabetes mellitus
 MOA: Lowers the blood sugar by stimulating glucose uptake
by cells, tissues, muscles(especially by skeletal muscles), fat
and by inhibiting glucose production by the liver.
 Standard dose:40IU/ml SC
 ADR: Hypoglycemia, hypersensitivity reactions, visual
disturbances, feeling hungry, dizziness.
 CI: Hypoglycemia, insulin allergic or any ingredient in
medicine, hepatic and renal impairment.
APO.METFORMIN(T.METFORMIN)500mg P/O
 Category: Anti- diabetic
 Indication: Type 2 Diabetes mellitus
 MOA: Decreasing the amount of glucose absorbed from the
intestine, lowering the amount of sugar created/produced by
the liver and facilitating entry of sugar into the cells.
 Standard dose: 500 mg P/O
 ADR :Lactic acidosis, hypoglycemia, loss of appetite, nausea
, vomiting , hepatotoxicity.
 CI : Type 1 Diabetes mellitus, hepatic and renal impairment ,
alcoholic.
T.TELMA (T.TELMISARTAN) 40 mg P/O
 Category: Antihypertensive
 Indication: Hypertension
 MOA: Inhibiting the binding of angiotensin II to its receptors
and hence prevents BP from raising by relaxing and widening
the blood vessels.
 Standard dose: 40 mg P/O
 ADR: Hypersensitivity reactions, thrombocytopenia , anemia,
hyperkalemia, anaphylaxis ,angioedema.
 CI : Hypersensitivity, renal and hepatic impairment, renal
artery stenosis , severe CHF.
CAP.ECOSPIRIN AV 75 (ASPIRIN+ATORVASTATIN)
 Category : Statins
 Indication: Prevention of heart attack and stroke
 MOA: Atorvastatin inhibits HMG CoA reductase and there by
reduces cholesterol synthesis. Aspirin prevents platelets from
sticking together and decreases the formation of harmful
blood clot.
 Standard dose: 75/10 mg per day P/O
 ADR: Abdominal pain, indigestion, constipation, flatulence,
increased risk of bleeding.
 CI: Acute liver disease, dengue fever, hypersensitivity .
T.OPTINEURON (MULTIVITAMIN) 15mg
P/O
 Category: Multivitamin
 Indication: Vit.B12 deficiency
 MOA :Improve blood circulation and oxygen saturation . It has
good influence on CNS.
 Standard dose : 10-25 mg/day P/O
 ADR:
 CI: Hypersensitivity
T.DOLO (PARACETAMOL)650mg P/O
 Category: Analgesic and antipyretic
 Indication : Head ache ,body pain , common cold
 MOA: Blocking the release of certain chemical messenger
that cause pain and fever.
 Standard dose: 500-1000mg every 4-6hrs P/O
 ADR : Bleeding, breathing problems, itching mouth ulcer, skin
rash.
 CI: Liver damage , allergy to it or its ingredients.
PLAN
SHORT TERM GOALS:
To reduce high blood glucose level, blood pressure and cholesterol level.
To relief symptoms associated like pain, weakness, headache etc.
LONG TERM GOALS:
To control long term Micro and Macro vascular complications of DM
To Prevent the development of cardiovascular diseases.
To improve quality of life.
To reduce the morbidity and mortality.
MONITORING PARAMETERS
 THERAPEUTIC MONITORING :
BP
FBS
RBS
HbA1c
Lipid Profile
Urine Microalbumin to rule out Diabetic Retinopathy
ECG
TOXICITY MONITORING:
Renal function test
Liver Function test
POINTS TO PATIENT
DISEASE:
You have been diagnosed with hyperlipidemia that is increased
level of cholesterol, type 2 diabetes mellitus that is increased blood glucose
level and hypertension that is increased blood pressure. These conditions can
be maintained by following proper medications along with proper dietary
management and lifestyle modification.
DRUGS:
 The prescribed medications should be taken regularly to control the
complications.
 Do not skip any medications.
 In case of missed dose don’t take two drugs at a time as it may lead
to further complications.
 Always keep sugar candy with you, If you feel any Hypoglycemic
symptoms like confusion, dizziness, sweating, Tired then
immediately take those candies
 T. Telma can make you feel dizzy for the first few days, Rise slowly
if you have been sitting and lying for a long time
 Even if you feel relieved don’t stop the medications your own,
consult your physician.
LIFESTYLE MODIFICATIONS
 Follow American Diabetic Association Diet to control DM.
 Avoid intake of sugar.
 Reduce intake of carbohydrate rich food like rice instead you can prefer fibres rich food
like wheat.
 Follow DASH Therapy that is Dietary approach to stop Hypertension.
 Reduce the intake of Salt in your diet to less than 1 tablespoon daily.
 Manage stress.
 Reduce the amount of saturated and total fat such as oil, dairy products in the diet.
 Getting regular aerobic exercise for 30 minutes.
 Restrict daily intake of alcohol.
 Since diabetic feet problems are more likely to occur, never go on bare foot or avoid
trauma to feet by cutting toe nails and wearing shoes that fit properly. Also keep the foot
clean and dry before going to bed, as there are chances of getting diabetic foot ulcer.
 DISCHARGE MEDICATIONS:
The following drugs are to be continued-
 T. METFORMIN 500mg 1-0-1
Given for high blood sugar.
To be taken twice morning & night 15 minutes before food.
 T. TELMISARTAN 40mg 0-1-0
Given for high bp.
To be taken once in the afternoon after 30 minutes of lunch.
 T. ATORVASTATIN 10mg 0-0-1
Given for high cholesterol level.
To be taken once in the night after food.
 T. OPTINEURON 15mg 1-0-1
Given for weakness.
To be taken twice morning & night after food.
 T. PARACETAMOL 650mg ss (whenever necessary)
Given for pain.
FOLLOW-UP
Review in medical OPD after one month.
THANK YOU

More Related Content

Similar to EXAM CASE PRESENTATION.pptx

Pediatric Type 2 Diabetes Mellitus. BY DR SAYED ISMAIL
Pediatric Type 2 Diabetes Mellitus. BY  DR SAYED ISMAILPediatric Type 2 Diabetes Mellitus. BY  DR SAYED ISMAIL
Pediatric Type 2 Diabetes Mellitus. BY DR SAYED ISMAILSayed Ahmed
 
Dyslipdiemia for scribd.pptx
Dyslipdiemia for scribd.pptxDyslipdiemia for scribd.pptx
Dyslipdiemia for scribd.pptxDanLee970027
 
diabetes mellitus by Tushar 202345.pptx
diabetes mellitus by Tushar 202345.pptxdiabetes mellitus by Tushar 202345.pptx
diabetes mellitus by Tushar 202345.pptxTushar Mankar
 
Revise Family Case Presentation Final
Revise Family Case Presentation   FinalRevise Family Case Presentation   Final
Revise Family Case Presentation Finalliza mariposque
 
Dyslipidaemia presentation
Dyslipidaemia presentationDyslipidaemia presentation
Dyslipidaemia presentationrajeetam123
 
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaaCaso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaaBrunoHernndez16
 
Diabetes prof ui-hcs
Diabetes prof ui-hcsDiabetes prof ui-hcs
Diabetes prof ui-hcsSonam Yeshi
 
Highlights of ADA guidelines 2015 in Diabetes management
Highlights of ADA guidelines 2015 in Diabetes managementHighlights of ADA guidelines 2015 in Diabetes management
Highlights of ADA guidelines 2015 in Diabetes managementAhmed Elmoughazy
 
Seminar nada pdf.pdf
Seminar nada pdf.pdfSeminar nada pdf.pdf
Seminar nada pdf.pdfNadaSAlotibi
 
A case study on anemia with congestive heart failure
A case study on anemia with congestive heart failureA case study on anemia with congestive heart failure
A case study on anemia with congestive heart failuremartinshaji
 
Presentation a bout diabetes
Presentation a bout diabetes   Presentation a bout diabetes
Presentation a bout diabetes zahraaesmat
 

Similar to EXAM CASE PRESENTATION.pptx (20)

Pediatric Type 2 Diabetes Mellitus. BY DR SAYED ISMAIL
Pediatric Type 2 Diabetes Mellitus. BY  DR SAYED ISMAILPediatric Type 2 Diabetes Mellitus. BY  DR SAYED ISMAIL
Pediatric Type 2 Diabetes Mellitus. BY DR SAYED ISMAIL
 
Treatment & Prevention 6
Treatment & Prevention 6Treatment & Prevention 6
Treatment & Prevention 6
 
Dyslipdiemia for scribd.pptx
Dyslipdiemia for scribd.pptxDyslipdiemia for scribd.pptx
Dyslipdiemia for scribd.pptx
 
diabetes mellitus by Tushar 202345.pptx
diabetes mellitus by Tushar 202345.pptxdiabetes mellitus by Tushar 202345.pptx
diabetes mellitus by Tushar 202345.pptx
 
1 drugs for dyslipidymias
1 drugs for dyslipidymias 1 drugs for dyslipidymias
1 drugs for dyslipidymias
 
3-170714225337.pdf
3-170714225337.pdf3-170714225337.pdf
3-170714225337.pdf
 
Revise Family Case Presentation Final
Revise Family Case Presentation   FinalRevise Family Case Presentation   Final
Revise Family Case Presentation Final
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Dyslipidaemia presentation
Dyslipidaemia presentationDyslipidaemia presentation
Dyslipidaemia presentation
 
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaaCaso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
 
Dyslipidemia
DyslipidemiaDyslipidemia
Dyslipidemia
 
Diabetes prof ui-hcs
Diabetes prof ui-hcsDiabetes prof ui-hcs
Diabetes prof ui-hcs
 
Cardiovascular Risk Factors and Hypertension
Cardiovascular Risk Factors and HypertensionCardiovascular Risk Factors and Hypertension
Cardiovascular Risk Factors and Hypertension
 
Highlights of ADA guidelines 2015 in Diabetes management
Highlights of ADA guidelines 2015 in Diabetes managementHighlights of ADA guidelines 2015 in Diabetes management
Highlights of ADA guidelines 2015 in Diabetes management
 
Seminar nada pdf.pdf
Seminar nada pdf.pdfSeminar nada pdf.pdf
Seminar nada pdf.pdf
 
A case study on anemia with congestive heart failure
A case study on anemia with congestive heart failureA case study on anemia with congestive heart failure
A case study on anemia with congestive heart failure
 
Diabetes
DiabetesDiabetes
Diabetes
 
Dm talk npt,tmo)
Dm talk npt,tmo)Dm talk npt,tmo)
Dm talk npt,tmo)
 
htn.pptx
htn.pptxhtn.pptx
htn.pptx
 
Presentation a bout diabetes
Presentation a bout diabetes   Presentation a bout diabetes
Presentation a bout diabetes
 

Recently uploaded

COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxannathomasp01
 
AIM of Education-Teachers Training-2024.ppt
AIM of Education-Teachers Training-2024.pptAIM of Education-Teachers Training-2024.ppt
AIM of Education-Teachers Training-2024.pptNishitharanjan Rout
 
PANDITA RAMABAI- Indian political thought GENDER.pptx
PANDITA RAMABAI- Indian political thought GENDER.pptxPANDITA RAMABAI- Indian political thought GENDER.pptx
PANDITA RAMABAI- Indian political thought GENDER.pptxakanksha16arora
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxEsquimalt MFRC
 
UGC NET Paper 1 Unit 7 DATA INTERPRETATION.pdf
UGC NET Paper 1 Unit 7 DATA INTERPRETATION.pdfUGC NET Paper 1 Unit 7 DATA INTERPRETATION.pdf
UGC NET Paper 1 Unit 7 DATA INTERPRETATION.pdfNirmal Dwivedi
 
Economic Importance Of Fungi In Food Additives
Economic Importance Of Fungi In Food AdditivesEconomic Importance Of Fungi In Food Additives
Economic Importance Of Fungi In Food AdditivesSHIVANANDaRV
 
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdfFICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdfPondicherry University
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Jisc
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxJisc
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxDr. Ravikiran H M Gowda
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jisc
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17Celine George
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024Elizabeth Walsh
 
What is 3 Way Matching Process in Odoo 17.pptx
What is 3 Way Matching Process in Odoo 17.pptxWhat is 3 Way Matching Process in Odoo 17.pptx
What is 3 Way Matching Process in Odoo 17.pptxCeline George
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and ModificationsMJDuyan
 
21st_Century_Skills_Framework_Final_Presentation_2.pptx
21st_Century_Skills_Framework_Final_Presentation_2.pptx21st_Century_Skills_Framework_Final_Presentation_2.pptx
21st_Century_Skills_Framework_Final_Presentation_2.pptxJoelynRubio1
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17Celine George
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxmarlenawright1
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxCeline George
 

Recently uploaded (20)

COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
 
VAMOS CUIDAR DO NOSSO PLANETA! .
VAMOS CUIDAR DO NOSSO PLANETA!                    .VAMOS CUIDAR DO NOSSO PLANETA!                    .
VAMOS CUIDAR DO NOSSO PLANETA! .
 
AIM of Education-Teachers Training-2024.ppt
AIM of Education-Teachers Training-2024.pptAIM of Education-Teachers Training-2024.ppt
AIM of Education-Teachers Training-2024.ppt
 
PANDITA RAMABAI- Indian political thought GENDER.pptx
PANDITA RAMABAI- Indian political thought GENDER.pptxPANDITA RAMABAI- Indian political thought GENDER.pptx
PANDITA RAMABAI- Indian political thought GENDER.pptx
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
UGC NET Paper 1 Unit 7 DATA INTERPRETATION.pdf
UGC NET Paper 1 Unit 7 DATA INTERPRETATION.pdfUGC NET Paper 1 Unit 7 DATA INTERPRETATION.pdf
UGC NET Paper 1 Unit 7 DATA INTERPRETATION.pdf
 
Economic Importance Of Fungi In Food Additives
Economic Importance Of Fungi In Food AdditivesEconomic Importance Of Fungi In Food Additives
Economic Importance Of Fungi In Food Additives
 
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdfFICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
What is 3 Way Matching Process in Odoo 17.pptx
What is 3 Way Matching Process in Odoo 17.pptxWhat is 3 Way Matching Process in Odoo 17.pptx
What is 3 Way Matching Process in Odoo 17.pptx
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
21st_Century_Skills_Framework_Final_Presentation_2.pptx
21st_Century_Skills_Framework_Final_Presentation_2.pptx21st_Century_Skills_Framework_Final_Presentation_2.pptx
21st_Century_Skills_Framework_Final_Presentation_2.pptx
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 

EXAM CASE PRESENTATION.pptx

  • 2. DEMOGRAPHIC DETAILS Patient Name :XYZ Age : 53 years Gender : Male Weight : 89 kg Height : 172 cm BMI : 30kg/m2 (Obese) DOA : 21.12.2020 DOD : 24.12.2020
  • 3. PROBLEM LIST Hypertension Type 2 Diabetes Mellitus Hyperlipidemia
  • 4. SUBJECTIVE EVIDENCE COMPLAINTS ON ADMISSION:  Generalised weakness since 1 month.  Instability while walking.  Excessive sweating.  Rapid breathing.  Chronic headache since 1 week.
  • 5. OBJECTIVE EVIDENCE PHYSICAL EXAMINATION : Conscious , Co-Operative P-I-C-CL-E (-) MEDICAL HISTORY: Type 2 Diabetes mellitus since 1 years. Hypertension since 2 year. MEDICATION HISTORY: GLIMEPIRIDE 2mg 1-0-1 ATENOLOL 50mg 0-1-0  SOCIAL HISTORY: Alcoholic  FAMILY HISTORY: Nil
  • 6. GENERAL EXAMINATION VITAL SIGNS: Blood pressure -160/100 mmHg. Respiratory rate - 27 cycles/min. Heart rate - 84 bpm. Temperature - 99° F.
  • 7. LABORATORY INVESTIGATIONS BLOOD GLUCOSE: RBS (110-180 mg/dl) : 310mg/dl FBS ( 70- 100 mg/dl) : 160 mg/dl HbA1c (4-6) : 7.8 LIPID PROFILE: TCh ( 120-200 mg/dl) : 280mg/dl TGs ( upto 170 mg/dl) : 240mg/dl HDL ( 40-60 mg/dl) : 34 mg/dl LDL ( 100-160 mg/dl) : 204 mg/dl
  • 8. HAEMATOLOGY: RBC (4.5-5.5 million cells/cmm) : 5.3 WBC (4,000-11,000 cells/cmm) :7000 Platelet(1.5L-3.0L) :2.5L Hb ( 13.5- 17.5 g/dl ) : 14.6 g/dl ESR ( 0-20 mm/h) : 20 mm/h LIVER: T.Bili (0.2-1.2 mg/dl) :0.24 mg/dl D.Bili (0-0.3 mg/dl) :0.08 mg/dl ALP (110-310 IU/L) :290 IU/L Albumin (3.2-5.5 g/dl) :4.8 g/dl Globulin(1.8-3.4 g/dl) : 3.0g/dl
  • 9. RENAL FUNCTION TESTS: Urea (10-45 mg/dl) : 38mg/dl Serum creatinine (0.4-1.4 mg/dl) :1.0 mg/dl ELECTROLYTES: Na (135-145 mEq/L) :140 mEq/L K (3.5-5 mEq/L) :3.8mEq/L Ca (8.8-10.2 mg/L) :9.2 mg/dl
  • 10. DAILY INVESTIGATION CHART: DAY INVESTIGATIONS DAY 2 FBS - 150mg/dl BP - 160/95 mmHg TC - 230 mg/dl LDL - 185 mg/dl HDL - 38 mg/dl DAY 3 FBS - 140 mg/dl BP - 140/90 mmHg TC - 218 mg/dl LDL - 170 mg/dl HDL - 48 mg/dl DAY 4 FBS - 140mg/dl BP - 140/85 mg/dl TC - 204 mg/dl LDL - 164 mg/dl HDL - 54 mg/dl
  • 12. ASSESSMENT DIAGNOSIS: Based on the subjective and objective evidence the patient was diagnosed with Type 2 Diabetes mellitus, Hypertension along with Hyperlipidemia. ETIOLOGY: Age Alcoholic
  • 13. CURRENT THERAPY The Following Medications have been Prescribed to the Patient- GENERIC NAME BRAND NAME DOSE ROA FREQUENCY DURATION DAY1 DAY2 DAY3 DAY4 INSULIN INJ. H.ACTRAPID (40IU/ml) 8U SC 1-1-1   T.METFORMIN APO.METFORM IN 500 mg P/O 0-0-1     T.TELMISARTAN T.TELMA 40 mg P/O 0-1-0     ASPIRIN+ATORV ASTATIN CAP.ECOSPRIN AV 75 75 mg/ P/O 10 mg 0-0-1     MULTIVITAMIN T.OPTINEURON 15 mg P/O 1-0-1     PARACETAMOL T.DOLO 650mg P/O 1-0-0   SOS
  • 14. INJ. H.ACTRAPID(40IU/ml) SC  Category: Anti – diabetic  Indication: Diabetes mellitus  MOA: Lowers the blood sugar by stimulating glucose uptake by cells, tissues, muscles(especially by skeletal muscles), fat and by inhibiting glucose production by the liver.  Standard dose:40IU/ml SC  ADR: Hypoglycemia, hypersensitivity reactions, visual disturbances, feeling hungry, dizziness.  CI: Hypoglycemia, insulin allergic or any ingredient in medicine, hepatic and renal impairment.
  • 15. APO.METFORMIN(T.METFORMIN)500mg P/O  Category: Anti- diabetic  Indication: Type 2 Diabetes mellitus  MOA: Decreasing the amount of glucose absorbed from the intestine, lowering the amount of sugar created/produced by the liver and facilitating entry of sugar into the cells.  Standard dose: 500 mg P/O  ADR :Lactic acidosis, hypoglycemia, loss of appetite, nausea , vomiting , hepatotoxicity.  CI : Type 1 Diabetes mellitus, hepatic and renal impairment , alcoholic.
  • 16. T.TELMA (T.TELMISARTAN) 40 mg P/O  Category: Antihypertensive  Indication: Hypertension  MOA: Inhibiting the binding of angiotensin II to its receptors and hence prevents BP from raising by relaxing and widening the blood vessels.  Standard dose: 40 mg P/O  ADR: Hypersensitivity reactions, thrombocytopenia , anemia, hyperkalemia, anaphylaxis ,angioedema.  CI : Hypersensitivity, renal and hepatic impairment, renal artery stenosis , severe CHF.
  • 17. CAP.ECOSPIRIN AV 75 (ASPIRIN+ATORVASTATIN)  Category : Statins  Indication: Prevention of heart attack and stroke  MOA: Atorvastatin inhibits HMG CoA reductase and there by reduces cholesterol synthesis. Aspirin prevents platelets from sticking together and decreases the formation of harmful blood clot.  Standard dose: 75/10 mg per day P/O  ADR: Abdominal pain, indigestion, constipation, flatulence, increased risk of bleeding.  CI: Acute liver disease, dengue fever, hypersensitivity .
  • 18. T.OPTINEURON (MULTIVITAMIN) 15mg P/O  Category: Multivitamin  Indication: Vit.B12 deficiency  MOA :Improve blood circulation and oxygen saturation . It has good influence on CNS.  Standard dose : 10-25 mg/day P/O  ADR:  CI: Hypersensitivity
  • 19. T.DOLO (PARACETAMOL)650mg P/O  Category: Analgesic and antipyretic  Indication : Head ache ,body pain , common cold  MOA: Blocking the release of certain chemical messenger that cause pain and fever.  Standard dose: 500-1000mg every 4-6hrs P/O  ADR : Bleeding, breathing problems, itching mouth ulcer, skin rash.  CI: Liver damage , allergy to it or its ingredients.
  • 20. PLAN SHORT TERM GOALS: To reduce high blood glucose level, blood pressure and cholesterol level. To relief symptoms associated like pain, weakness, headache etc. LONG TERM GOALS: To control long term Micro and Macro vascular complications of DM To Prevent the development of cardiovascular diseases. To improve quality of life. To reduce the morbidity and mortality.
  • 21. MONITORING PARAMETERS  THERAPEUTIC MONITORING : BP FBS RBS HbA1c Lipid Profile Urine Microalbumin to rule out Diabetic Retinopathy ECG TOXICITY MONITORING: Renal function test Liver Function test
  • 22. POINTS TO PATIENT DISEASE: You have been diagnosed with hyperlipidemia that is increased level of cholesterol, type 2 diabetes mellitus that is increased blood glucose level and hypertension that is increased blood pressure. These conditions can be maintained by following proper medications along with proper dietary management and lifestyle modification.
  • 23. DRUGS:  The prescribed medications should be taken regularly to control the complications.  Do not skip any medications.  In case of missed dose don’t take two drugs at a time as it may lead to further complications.  Always keep sugar candy with you, If you feel any Hypoglycemic symptoms like confusion, dizziness, sweating, Tired then immediately take those candies  T. Telma can make you feel dizzy for the first few days, Rise slowly if you have been sitting and lying for a long time  Even if you feel relieved don’t stop the medications your own, consult your physician.
  • 24. LIFESTYLE MODIFICATIONS  Follow American Diabetic Association Diet to control DM.  Avoid intake of sugar.  Reduce intake of carbohydrate rich food like rice instead you can prefer fibres rich food like wheat.  Follow DASH Therapy that is Dietary approach to stop Hypertension.  Reduce the intake of Salt in your diet to less than 1 tablespoon daily.  Manage stress.  Reduce the amount of saturated and total fat such as oil, dairy products in the diet.  Getting regular aerobic exercise for 30 minutes.  Restrict daily intake of alcohol.  Since diabetic feet problems are more likely to occur, never go on bare foot or avoid trauma to feet by cutting toe nails and wearing shoes that fit properly. Also keep the foot clean and dry before going to bed, as there are chances of getting diabetic foot ulcer.
  • 25.  DISCHARGE MEDICATIONS: The following drugs are to be continued-  T. METFORMIN 500mg 1-0-1 Given for high blood sugar. To be taken twice morning & night 15 minutes before food.  T. TELMISARTAN 40mg 0-1-0 Given for high bp. To be taken once in the afternoon after 30 minutes of lunch.
  • 26.  T. ATORVASTATIN 10mg 0-0-1 Given for high cholesterol level. To be taken once in the night after food.  T. OPTINEURON 15mg 1-0-1 Given for weakness. To be taken twice morning & night after food.  T. PARACETAMOL 650mg ss (whenever necessary) Given for pain.
  • 27. FOLLOW-UP Review in medical OPD after one month.